Cargando…
First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis
INTRODUCTION: To assess the risk of recurrent dacryocystitis after first-onset dacryocystitis and to obtain a demographic profile and treatment characteristic for patients with first-onset dacryocystitis. METHODS: A retrospective study was performed on patients who had first-onset dacryocystitis dur...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437150/ https://www.ncbi.nlm.nih.gov/pubmed/35788550 http://dx.doi.org/10.1007/s40123-022-00544-5 |
_version_ | 1784781522348277760 |
---|---|
author | Engelsberg, Karl Sadlon, Mikael |
author_facet | Engelsberg, Karl Sadlon, Mikael |
author_sort | Engelsberg, Karl |
collection | PubMed |
description | INTRODUCTION: To assess the risk of recurrent dacryocystitis after first-onset dacryocystitis and to obtain a demographic profile and treatment characteristic for patients with first-onset dacryocystitis. METHODS: A retrospective study was performed on patients who had first-onset dacryocystitis during the years 2010–2013. Patients were followed up for 3 years. The analysis focused on the recurrence of dacryocystitis, demographics, medical treatment, and choice of lacrimal surgery. RESULTS: The inclusion criteria were met by 52 patients. Of these 15 (29%) had one or more recurrence of dacryocystitis, and 18 patients (34.6%) underwent lacrimal surgery. The mean age was 51.6 years (median 55.5, range 0–93). The female-to-male ratio was slightly under 3:1 (73.1%). The most frequent medical treatment was flucloxacillin capsules combined with chloramphenicol eye drops or ointment. CONCLUSIONS: The majority of patients with first-onset dacryocystitis had no further episodes of dacryocystitis. Some patients experienced recurrent and complicated infections requiring surgery and were thus a significant burden on the healthcare services. Various surgical options were used to clear the nasolacrimal obstruction causing dacryocystitis. Dacryocystorhinostomy was the most common procedure and showed excellent success rate. |
format | Online Article Text |
id | pubmed-9437150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-94371502022-09-03 First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis Engelsberg, Karl Sadlon, Mikael Ophthalmol Ther Original Research INTRODUCTION: To assess the risk of recurrent dacryocystitis after first-onset dacryocystitis and to obtain a demographic profile and treatment characteristic for patients with first-onset dacryocystitis. METHODS: A retrospective study was performed on patients who had first-onset dacryocystitis during the years 2010–2013. Patients were followed up for 3 years. The analysis focused on the recurrence of dacryocystitis, demographics, medical treatment, and choice of lacrimal surgery. RESULTS: The inclusion criteria were met by 52 patients. Of these 15 (29%) had one or more recurrence of dacryocystitis, and 18 patients (34.6%) underwent lacrimal surgery. The mean age was 51.6 years (median 55.5, range 0–93). The female-to-male ratio was slightly under 3:1 (73.1%). The most frequent medical treatment was flucloxacillin capsules combined with chloramphenicol eye drops or ointment. CONCLUSIONS: The majority of patients with first-onset dacryocystitis had no further episodes of dacryocystitis. Some patients experienced recurrent and complicated infections requiring surgery and were thus a significant burden on the healthcare services. Various surgical options were used to clear the nasolacrimal obstruction causing dacryocystitis. Dacryocystorhinostomy was the most common procedure and showed excellent success rate. Springer Healthcare 2022-07-05 2022-10 /pmc/articles/PMC9437150/ /pubmed/35788550 http://dx.doi.org/10.1007/s40123-022-00544-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Engelsberg, Karl Sadlon, Mikael First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title | First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title_full | First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title_fullStr | First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title_full_unstemmed | First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title_short | First-Onset Dacryocystitis: Characterization, Treatment, and Prognosis |
title_sort | first-onset dacryocystitis: characterization, treatment, and prognosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437150/ https://www.ncbi.nlm.nih.gov/pubmed/35788550 http://dx.doi.org/10.1007/s40123-022-00544-5 |
work_keys_str_mv | AT engelsbergkarl firstonsetdacryocystitischaracterizationtreatmentandprognosis AT sadlonmikael firstonsetdacryocystitischaracterizationtreatmentandprognosis |